kasugamycin has been researched along with Alveolitis, Fibrosing in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Akosman, B; Elias, JA; Herzog, EL; Kamle, S; Kim, MO; Lee, CG; Lee, CM; Lee, JH; Park, JW; Peng, XY | 1 |
1 other study(ies) available for kasugamycin and Alveolitis, Fibrosing
| Article | Year |
|---|---|
Kasugamycin Is a Novel Chitinase 1 Inhibitor with Strong Antifibrotic Effects on Pulmonary Fibrosis.
Topics: Aminoglycosides; Animals; Antifibrotic Agents; Bleomycin; Chitinases; Fibroblasts; Humans; Lung; Mice; Mice, Inbred C57BL; Pulmonary Fibrosis; Transforming Growth Factor beta | 2022 |